EGFR and non-small cell lung carcinoma: The median value of drug concentrations for patients who did not experience adverse reactions during treatment and those who experienced adverse reactions were 997.0 and 828.6 ng/mL, respectively (P=0.538).<h4>Conclusions</h4>Icotinib demonstrates good therapeutic effect and tolerable toxicity on the EGFR gene mutant NSCLC.